Glucocorticoids in Alzheimer's disease. The story so far

Drugs and Aging

Volumn 12, Issue 1, 1998, Pages 1-6

  Aisen, Paul S ^a   Pasinetti, Giulio M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; GLUCOCORTICOID; PREDNISONE;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NERVE DEGENERATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GLUCOCORTICOIDS; HUMANS;

EID: 0031973405     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812010-00001     Document Type: Review

References (59)

1. Rogers J, Civin WH, Styren SD, et al. Immune-related mechanisms of Alzheimer's disease pathogenesis. In: Khachaturian ZS, Blass JB, editors. Alzheimer's disease: new treatment strategies. New York: Marcel Dekker. 1992: 147-63
2. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151: 1105-13
3. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991; 285: 111-4
4. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today 1991; 12: 217-9
5. Potter H, Nelson RB, Das S, et al. The involvement of proteases. protease inhibitors, and an acute phase response in Alzheimer's disease. Ann N Y Acad Sci 1992; 674: 161-73
6. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996; 17: 707-16
7. Rogers J, Webster S, Lue LF, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 17: 681-6
8. McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79: 195-200
9. Fagarasan MO, Aisen PS. IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res 1996; 723: 231-4
10. Schultz J, Schaller J, McKinley M, et al. Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism. Neurosci Lett 1994; 175: 99-102
11. Oda T, Lehrer-Graiwer J, Finch CE, et al. Complement and β-amyloid (aβ) neurotoxicity in vitro: a model for Alzheimer disease. Alzheim Res 1995; 1: 29-34
12. Giulian D, Li J, Leara B, et al. Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem Int 1994; 25: 227-33
13. London JA, Biegel D, Pachter JS. Neurocytopathic effects of beta-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci U S A 1996; 93: 4147-52
14. Griffin WS, Sheng JG, Roberts GW, et al. Interleukin-1 expression in different plaque types in Alzheimer's diseases: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276-81
15. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993; 90: 10061-5
16. Aisen PS, Marin D, Altstiel L, et al. A pilot study of prednisone in Alzheimer's disease. Dementia 1996; 7: 201-6
17. Sapolsky RM, McEwen BS. Stress, glucocorticoids and their role in degenerative changes in the aging hippocampus. In: Crook T, Bartus R, Ferris S, et al., editors. Treatment development strategies for Alzheimer's disease. New Canaan (CT): Mark Powley Associates, 1986: 151-72
18. Sapolsky RM. Why stress is bad for your brain. Science 1997; 273: 749-50
19. Landfield PW, Eldridge JC. Evolving aspects of the glucocorticoid hypothesis of brain aging: hormonal modulation of neuronal calcium homeostasis. Neurobiol Aging 1994; 15: 579-88
20. McEwen BS, Angulo J, Cameron H, et al. Paradoxical effects of adrenal steroids on the brain: protection versus degeneration. Biol Psychiatry 1992; 31: 177-99
21. Magarinos AM, Orchinik M, McEwen BS. Oral administration of corticosterone mimics effects of stress on hippocampal CA3c dendritic structure [abstract]. 25th Annual Meeting of the Society for Neuroscience: 1995 Nov 11-16: San Diego. Washington, DC: Society for Neuroscience, 1995: 1948
22. Starkman MN, Gebarski SS, Berent S, et al. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32: 756-65
23. Davis KL, Davis BM, Greenwald BS, et al. Cortisol and Alzheimer's disease: I. Basal studies. Am J Psychiatry 1986; 143: 300-5
24. Hollander E, Mohs RC, Davis KL. Cholinergic approaches to the treatment of Alzheimer's disease. Br Med Bull 1986; 42: 97-100
25. Newcomer JW, Craft S, Hershey T, et al. Glucocorticoid-induced impairment in declarative memory performance in adult humans. J Neurosci 1994; 14: 2047-53
26. Denburg SD, Carbotte RM, Denburg JD. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1311-20
27. Matsubara E, Hirai S, Amari M, et al. Alpha-1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28: 561-7
28. 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992; 32: 193-7
29. Hinds TR, Kukull WA, Van Belle G, et al. Relationship between serum α1-antichymotrypsin and Alzheimer's disease. Neurobiol Aging 1994; 15: 21-7
30. Altstiel LD, Lawlor B, Mohs R, et al. Elevated alpha1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia 1995; 6: 17-20
31. Lieberman J, Schleissner L, Tachiki KH, et al. Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 1995; 16: 747-53
32. Pirttila T, Mehta PD, Frey H, et al. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994; 15: 313-7
33. Kuiper MA, Van Kamp GJ, Bergmans PLM, et al. Serum α1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993; 6: 145-9
34. Lawlor BA, Swanwick GRJ, Feighery C, et al. Acute phase reactants in Alzheimer's disease. Biol Psychiatry 1996; 39: 1051-2
35. Fagarasan MO, Sevilla D, Baruch B, et al. Plasma C3a levels in Alzheimer's disease. Alzheim Res 1997; 3: 137-40
36. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
37. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4
38. Van Muiswinkel FL, Eikelenboom P. Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia? Drugs Aging 1996; 9: 1-7
39. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32
40. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAIDs use. Neurology 1997; 48: 626-32
41. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11
42. Tocco G, Freire O, Schreiber SS, et al. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol 1997; 144: 339-49
43. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86
44. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1-9
45. Wong PT-H, McGeer PL, McGeer EG. Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease. Neurochem Int 1992; 21: 197-202
46. Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996; 17: 801-8
47. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992; 89: 4888-92
48. Cao C, Matsumura K, Yamagata K, et al. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain: its possible role in the febrile response. Brain Res 1995; 697: 187-96
49. Nakayama M, Uchimura K, Zhu L, et al. Cyclooxygenase 2 promotes neuronal cell death after global ischemia in rat CA1 hippocampus [abstract]. 26th Annual Meeting of the Society for Neuroscience: 1996 Nov 16-21: Washington, DC. Washington, DC: Society for Neuroscience, 1996: 1670
50. Graham SH, Kawaguchi K, Zhu L, et al. Cyclooxygenase 2 is induced in rat brain after kainate induced seizures and promotes death in CA3 hippocampus [abstract]. 26th Annual Meeting of the Society for Neuroscience: 1996 Nov 16-21: Washington, DC. Washington, DC: Society for Neuroscience, 1996: 2088
51. Oka A, Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 1997; 8: 1161-4
52. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10
53. Giulian D, Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990; 27: 33-42
54. Zemer D, Pras M, Sonar E, et al. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001-5
55. Escalante A, Ehresmann GR, Quismorio FP. Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine. Arthritis Rheum 1991; 34: 920-2
56. Paydas S, Gonlusen G. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease. Nephron 1995; 71: 463-4
57. Aisen PS, Marin D, Fusco M, et al. A pilot study of colchicine in Alzheimer's disease. Alzheim Res 1996; 2: 153-6
58. Games D, Adams D, Alessandrini R, et al. Development of neuropathology similar to Alzheimer's disease in transgenic mice overexpressing the 717V-Fβ-amyloid precursor protein. Nature 1995; 373: 523-7
59. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996 Oct 4; 274: 99-102